MedX Health Corp Reports First Quarter 2009 Financial Results

    36% Gain in Q1 2009 Compared to Q4 2008

    MISSISSAUGA, ON, May 27 /CNW/ - MedX Health Corp., (TSXV.MDX) a global
leader in drug free, non-invasive low level laser and light therapy for tissue
repair and pain relief, today announced its results for the quarter ended
March 31, 2009.
    Revenue for the quarter ended March 31, 2009 was $351,575, an 18.9 %
increase over the same period in 2008 where revenue was $295,582. This revenue
also represents a 35.7% increase over revenues in the previous quarter. MedX
incurred a loss from continuing operations for the quarter of $408,458 or
$0.02 per share compared to a loss of $688,604 or $0.04 per share for the same
period in the prior year.
    "MedX continues to post strong revenue increases versus recent prior
periods in 2008," said Steven Guillen, chief executive officer and president
of MedX Health. "This quarter's strong growth is a direct result of Medx's
entry into the international marketplace as it made its first major shipments
into the European market after obtaining the CE mark approval for all its
products. Our two new strategic partnerships with Technology4Medicine and
Richmar/Naimco, continue to show excellent potential for future growth. We are
pleased with the revenue growth over the last nine months, especially in light
of the difficult market conditions. We expect to continue this trend of
revenue growth for the remainder of 2009."

    Recent Company Highlights:

    -   Received CE mark for all products, which allows MedX to begin selling
        in 27 countries associated with the European Community (MedX Health
        Receives CE Mark for Laser and Light Products, March 4, 2009).
    -   Launched IRB (Investigational Review Board) approved program for
        treating addictions; smoking, alcohol, and drug abuse. This
        incorporates the MedX acupuncture laser with the goal of expanding
        the scope of an individual practice to a full franchise opportunity
        (MedX Health Announces Initiation of Laser Acupuncture Study for
        Controlling Addiction, January 22, 2009).
    -   Achieved ISO re-certification, demonstrating to outside regulatory
        bodies that the highest quality standards are in place (MedX Health
        Receives CE Mark for Laser and Light Products, March 4, 2009).
    -   Announced a newly allowed wound healing patent covering a laser and
        light therapy apparatus and method for bone healing, bone growth
        stimulation, and bone cartilage regeneration (MedX Health Announces
        Patent Allowance for Use of Laser and Light Probe for Bone Healing,
        February 23, 2009),

    Canadian $                                          Q1 2009      Q1 2008
    Revenue                                             351,575      295,582
    Gross Margin %                                        54.2%        69.0%
    Loss from continued operations                     (403,364)    (687,144)
    Loss from discontinued operations                    (5,094)      (1,460)
    Loss for the period                                (408,458)    (688,604)
    Weighted Average no. of shares
     outstanding-basic                               27,128,527   15,043,937
    Loss per Common Share-basic and diluted              ($0.02)      ($0.04)

    About MedX Health Corp.

    MedX is a leading North American developer and manufacturer of low level
laser and light medical devices for the drug free and non-invasive treatment
of tissue damage and pain in numerous medical settings including dental,
rehabilitation and wound care. MedX is the world's only company focusing on
developing and delivering a broad cross-section of technologies and products
involved in healing using light therapy. MedX is committed to advocating for,
the bringing of non-invasive, drug-free healing nature of light to people
seeking relief from pain and other physical ailments.
    MedX's strategy is to build upon its success in bringing relief of
symptoms in a non-pharmacologic manner in the rehabilitation market through
key partnerships, acquisitions, strong patent protection as well as developing
and commercializing advanced products in the dental and wound-care markets
that will position the company to increase revenue. In addition, MedX plans to
accelerate the development of a new product aimed at the rapidly-growing wound
care market: its "Photobandage(TM)", a bandage technology that allows a wound
to be bathed in light, designed to enhance the healing process. The Company
intends to license this new technology to one or more major wound care
companies for further development of marketing and sales.
    Brand products are US FDA approved, Health Canada cleared, and CE Marked
and are produced in an ISO 9001 and 13485 certified manufacturing and testing
facility. For a complete profile of MedX Health Corp. and its products visit

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this press release.

    This press release contains "forward-looking information" within the
meaning of applicable Canadian securities legislation. Such forward-looking
information may include statements regarding the Company's future plans,
objectives, performance, growth, profits, operating expenses or its underlying
assumptions. Generally, forward-looking information can be identified by the
use of forward-looking terminology such as "plans", "expects", or "does not
expect", "is expected", "budget", "scheduled", "estimates", "forecasts",
"intends", "anticipates", or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might", or "will be taken", "occur", or "be
achieved". Forward-looking information is subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of MedX to be materially different from
those expressed or implied by such forward-looking information, including
uncertainty of successful development of new products, uncertainty of
successful manufacturing or marketing of products, uncertainty of commercial
acceptance of products, uncertainty concerning governmental regulation,
dependency on key employees and relationships, rapid technological changes,
foreign currency fluctuations. MedX does not undertake to update any
forward-looking information, except in accordance with applicable securities

    %SEDAR: 00017466E

For further information:

For further information: Investors: Steve Guillen, President and Chief
Executive Officer, MedX Health Corp., Phone: (905) 826-0766,; Media: Terri Clevenger, Continuum Health Communications,
Phone (203) 227-0209, Email:

Organization Profile

MedX Health Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890